KR102831250B1 - 근시 진행의 치료 - Google Patents

근시 진행의 치료 Download PDF

Info

Publication number
KR102831250B1
KR102831250B1 KR1020207022632A KR20207022632A KR102831250B1 KR 102831250 B1 KR102831250 B1 KR 102831250B1 KR 1020207022632 A KR1020207022632 A KR 1020207022632A KR 20207022632 A KR20207022632 A KR 20207022632A KR 102831250 B1 KR102831250 B1 KR 102831250B1
Authority
KR
South Korea
Prior art keywords
ophthalmic composition
copper
composition according
delete delete
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207022632A
Other languages
English (en)
Korean (ko)
Other versions
KR20200118426A (ko
Inventor
랜든 마이클 버
발라무랄리 케이. 암바티
사라 에이. 몰로키아
Original Assignee
유니버시티 오브 유타 리서치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 유타 리서치 파운데이션 filed Critical 유니버시티 오브 유타 리서치 파운데이션
Priority to KR1020257022145A priority Critical patent/KR20250109788A/ko
Publication of KR20200118426A publication Critical patent/KR20200118426A/ko
Application granted granted Critical
Publication of KR102831250B1 publication Critical patent/KR102831250B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020207022632A 2018-01-05 2019-01-07 근시 진행의 치료 Active KR102831250B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257022145A KR20250109788A (ko) 2018-01-05 2019-01-07 근시 진행의 치료

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862614230P 2018-01-05 2018-01-05
US62/614,230 2018-01-05
PCT/US2019/012501 WO2019136358A1 (en) 2018-01-05 2019-01-07 Treatment of myopic progression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257022145A Division KR20250109788A (ko) 2018-01-05 2019-01-07 근시 진행의 치료

Publications (2)

Publication Number Publication Date
KR20200118426A KR20200118426A (ko) 2020-10-15
KR102831250B1 true KR102831250B1 (ko) 2025-07-08

Family

ID=67143996

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207022632A Active KR102831250B1 (ko) 2018-01-05 2019-01-07 근시 진행의 치료
KR1020257022145A Pending KR20250109788A (ko) 2018-01-05 2019-01-07 근시 진행의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257022145A Pending KR20250109788A (ko) 2018-01-05 2019-01-07 근시 진행의 치료

Country Status (8)

Country Link
US (2) US11524032B2 (https=)
EP (1) EP3735209A4 (https=)
JP (3) JP7324208B2 (https=)
KR (2) KR102831250B1 (https=)
CN (1) CN112105320A (https=)
AU (2) AU2019205774B2 (https=)
CA (1) CA3087622A1 (https=)
WO (1) WO2019136358A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3426262B1 (en) * 2016-03-08 2023-08-23 University of Utah Research Foundation Cross-linking agents and associated methods
AU2019205774B2 (en) 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression
CN114364355A (zh) * 2019-07-11 2022-04-15 犹他大学研究基金会 多剂眼科制剂和治疗方法
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療
CN115282349A (zh) * 2022-07-05 2022-11-04 复旦大学附属眼耳鼻喉科医院 一种有利于改善孟加拉玫瑰红-绿光角膜胶原交联技术中cct降低的角膜交联试剂
CN115386105B (zh) * 2022-08-26 2024-03-22 昆明理工大学 多重酶活性纳米酶荧光水凝胶的制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102985A (zh) * 1993-11-23 1995-05-31 华中理工大学 一种防治近视的滴眼液
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
JPH04502012A (ja) * 1989-09-27 1992-04-09 モスコフスキ　ナウチノ―イススレドバテルスキ　インスティテュト　グラツィニフ　ボレツネイ　イメニ　ゲルムゴルツァ 進行性近視の治療用組成物
EP1159941A3 (en) * 1991-10-15 2003-09-17 Ista Pharmaceuticals, Inc. Formulations for use in enzyme-orthokeratology
AU7488898A (en) 1997-05-16 1998-12-08 Corrective Vision, Inc. Improved contact lens
WO1999045869A1 (en) * 1998-03-09 1999-09-16 Ista Pharmaceuticals, Inc. Use of corneal hardening agents in enzyme orthokeratology
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
AU2002257273A1 (en) * 2001-04-13 2002-10-28 Incyte Genomics, Inc. Enzymes
EP1397132A4 (en) 2001-05-25 2006-12-13 Valley Forge Pharmaceuticals I OPHTHALMIC PIRENZEPINE GEL
NZ540885A (en) * 2002-12-20 2009-02-28 Chakshu Res Inc Ophthalmic formulation for the prevention and treatment of ocular conditions
CN1518981A (zh) * 2003-07-23 2004-08-11 复旦大学附属眼耳鼻喉科医院 一种治疗近视的外用滴眼制剂
MXPA03011987A (es) * 2003-12-19 2005-06-23 Osio Sancho Alberto Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal.
US20060134226A1 (en) 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
US20060276777A1 (en) * 2005-04-08 2006-12-07 Coroneo Minas T Corneal shaping
US20080014278A1 (en) 2006-06-30 2008-01-17 Nucryst Pharmaceuticals Metal-containing formulations and methods of use
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
EP3858356A3 (en) * 2013-05-19 2021-12-01 Avedro, Inc. Systems, methods, and compositions for cross-linking
RU2635185C2 (ru) * 2013-12-17 2017-11-09 Иван Дмитриевич Захаров Фармацевтический препарат для профилактики и лечения прогрессирующей близорукости
SG11201608257RA (en) * 2014-04-09 2016-10-28 Universität Leipzig A device for a medical treatment of a sclera
US9421199B2 (en) 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
BR112017021374A2 (pt) * 2015-04-09 2018-07-03 Laboratori Baldacci S.P.A. ácido pirrolidona carboxílico (pca) para uso oftálmico
US10010502B2 (en) 2015-05-19 2018-07-03 Amorphex Therapeutics Llc Device that delivers a sustained low-dose of a myopia-suppressing drug, while preserving pupillary function and accommodation
US20200345542A1 (en) 2017-11-21 2020-11-05 Sydnexis, Inc. Ophthalmic composition and delivery device thereof
AU2019205774B2 (en) 2018-01-05 2025-01-02 University Of Utah Research Foundation Treatment of myopic progression
CN114364355A (zh) * 2019-07-11 2022-04-15 犹他大学研究基金会 多剂眼科制剂和治疗方法
TW202245810A (zh) * 2021-02-01 2022-12-01 美商艾維娜傳送系統公司 散光之治療
TW202302121A (zh) * 2021-02-11 2023-01-16 猶他大學研究基金會 近視之治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102985A (zh) * 1993-11-23 1995-05-31 华中理工大学 一种防治近视的滴眼液
WO2017155580A1 (en) * 2016-03-08 2017-09-14 University Of Utah Research Foundation Cross-linking agents and associated methods

Also Published As

Publication number Publication date
AU2019205774B2 (en) 2025-01-02
CA3087622A1 (en) 2019-07-11
AU2024278182A1 (en) 2025-01-02
JP7324208B2 (ja) 2023-08-09
AU2019205774A1 (en) 2020-08-06
JP2021509902A (ja) 2021-04-08
JP7655988B2 (ja) 2025-04-02
KR20250109788A (ko) 2025-07-17
EP3735209A4 (en) 2021-09-08
CN112105320A (zh) 2020-12-18
US11524032B2 (en) 2022-12-13
JP2023153905A (ja) 2023-10-18
JP2025111434A (ja) 2025-07-30
KR20200118426A (ko) 2020-10-15
US20230256012A1 (en) 2023-08-17
EP3735209A1 (en) 2020-11-11
US20210060059A1 (en) 2021-03-04
US12544400B2 (en) 2026-02-10
WO2019136358A1 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
KR102831250B1 (ko) 근시 진행의 치료
AU2023202236B2 (en) Cross-linking agents and associated methods
AU2020311441B2 (en) Multi-agent ocular formulations and treatment methods
US20240122974A1 (en) Treatment of myopia
HK40107891A (en) Cross-linking agents and associated methods

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)